ResMed Loses 5 of 6 Patent Challenges Against Cleveland Medical Devices
RMD is trading near its 52-week low of $180.265 (10% above the low).
Summary
The Patent Trial and Appeal Board ruled against ResMed in five of six inter partes review challenges it brought against Cleveland Medical Devices' patents. In four of those proceedings, the PTAB found ResMed failed to establish that the challenged claims were unpatentable. This outcome weakens ResMed's ability to invalidate patents that could pose competitive or licensing risks in its core sleep and respiratory care markets. The decision follows ResMed's recent $490 million MatrixCare divestiture and a strategic partnership with ŌURA, as the company sharpens its focus on sleep health. No specific upcoming legal milestones are known, but the ruling may embolden Cleveland Medical Devices in ongoing or future disputes.
At the time of this announcement, RMD was trading at $198.50 on NYSE in the Life Sciences sector, with a market capitalization of approximately $28.8B. The 52-week trading range was $180.27 to $293.81. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.